Dauer WT, Fahn S, Burke RE. The Diagnosis and Treatment of Tardive Disorders. Medical Update for Psychiatrists. 1998;3(4):119-125.
Esper CD, Factor SA. Failure of recognition of drug-induced parkinsonism in the elderly. Mov Disord. Online ahead of print Dec 7 2007.
Friedman JH, Fernandez HH, Trieschmann MM. Parkinsonism in a nursing home: underrecognition. J Geriatr Psychiatry Neurol. Mar 2004;17(1):39-41.
Lerner V, Libov I, Kaptsan A, Miodownik C, Dwolatzky T, Levine J. The prevalence of neuroleptic drug-induced tardive movement subsyndromes among schizophrenic and schizoaffective patients residing in the southern region of Israel. Isr J Psychiatry Relat Sci. 2007;44(1):20-28.
Kane JM. Tardive dyskinesia circa 2006. Am J Psychiatry. Aug 2006;163(8):1316-1318.
de Leon J. The effect of atypical versus typical antipsychotics on tardive dyskinesia: a naturalistic study. Eur Arch Psychiatry Clin Neurosci. Apr 2007;257(3):169-172.
Schwarz Pharma. Reglan tablet package insert.
Kaplan S, Staffa JA, Dal Pan GJ. Duration of therapy with metoclopramide: a prescription claims data study. Pharmacoepidemiol Drug Saf. Aug 2007;16(8):878-881.
Liou YJ, Wang YC, Chen JY, et al. Association analysis of polymorphisms in the N-methyl-D-aspartate (NMDA) receptor subunit 2B (GRIN2B) gene and tardive dyskinesia in schizophrenia. Psychiatry Res. Dec 3 2007;153(3):271-275.
Kulkarni SK, Naidu PS. Pathophysiology and drug therapy of tardive dyskinesia: current concepts and future perspectives. Drugs Today (Barc). Jan 2003;39(1):19-49.
Richardson MA, Bevans ML, Read LL, et al. Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men. Am J Psychiatry. Jun 2003;160(6):1117-1124.
Richardson MA, Small AM, Read LL, Chao HM, Clelland JD. Branched chain amino acid treatment of tardive dyskinesia in children and adolescents. J Clin Psychiatry. Jan 2004;65(1):92-96.
Burger ME, Fachinetto R, Wagner C, et al. Effects of diphenyl-diselenide on orofacial dyskinesia model in rats. Brain Res Bull. Jun 30 2006;70(2):165-170.
Bishnoi M, Chopra K, Kulkarni SK. Possible anti-oxidant and neuroprotective mechanisms of zolpidem in attenuating typical anti-psychotic-induced orofacial dyskinesia: a biochemical and neurochemical study. Prog Neuropsychopharmacol Biol Psychiatry. Jun 30 2007;31(5):1130-1138.
Rauchverger B, Isakov V, Jabarin M. Olanzapine-induced tardive dystonia successfully treated by tetrabenazine. J Neuropsychiatry Clin Neurosci. Fall 2007;19(4):484-485.
Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. Jan 15 2007;22(2):193-197.
Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry. Aug 1999;156(8):1279-1281.
Rathbone J, Soares-Weiser K. Anticholinergics for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev. 2006(4):CD003727.
Malik P, Andersen MB, Peacock L. The effects of dopamine D3 agonists and antagonists in a nonhuman primate model of tardive dyskinesia. Pharmacol Biochem Behav. Aug 2004;78(4):805-810.
Meco G, Fabrizio E, Epifanio A, et al. Levetiracetam in tardive dyskinesia. Clin Neuropharmacol. Sep-Oct 2006;29(5):265-268.
Vaddadi K, Hakansson K, Clifford J, Waddington J. Tardive dyskinesia and essential fatty acids. Int Rev Psychiatry. Apr 2006;18(2):133-143.
Lerner V, Miodownik C, Kaptsan A, et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study. J Clin Psychiatry. Nov 2007;68(11):1648-1654.
Zhang XY, Zhou DF, Cao LY, Xu CQ, Chen DC, Wu GY. The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trial. J Clin Psychopharmacol. Feb 2004;24(1):83-86.
Hennings JM, Krause E, Botzel K, Wetter TC. Successful treatment of tardive lingual dystonia with botulinum toxin: Case report and review of the literature. Prog Neuropsychopharmacol Biol Psychiatry. Online ahead of print Sep 18 2007.
